Document Detail


99mTc DPD Is the Preferential Bone Tracer for Diagnosis of Cardiac Transthyretin Amyloidosis.
MedLine Citation:
PMID:  22785530     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
ABSTRACT: We emphasize the role of Tc-99m-3,3-diphosphono-1,2-propanodicarboxylicacid (DPD) scintigraphy as a noninvasive tool to distinguish transthyretin (TTR)-related cardiac amyloidosis from other forms of cardiac amyloidosis. We report the case of a 76-year-old male patient suffering from congestive heart failure in whom imaging investigation by DPD scintigraphy showed a strong cardiac uptake highly suggestive of TTR amyloidosis variant. TTR-related cardiac amyloidosis was confirmed on myocardial biopsies by immunohistochemistry analysis. This case supports the growing interest in DPD scintigraphy for typing cardiac amyloidosis and for its contribution in the place of invasive myocardial biopsy.
Authors:
Pascal Rossi; Laurent Tessonnier; Yves Frances; Olivier Mundler; Brigitte Granel
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical nuclear medicine     Volume:  37     ISSN:  1536-0229     ISO Abbreviation:  Clin Nucl Med     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-12     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7611109     Medline TA:  Clin Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e209-10     Citation Subset:  IM    
Affiliation:
From the Departments of *Internal Medicine and †Nuclear Medicine, Public Hospitalsof Marseille, North Hospital, Marseille cedex, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Terminal Ileum Neuroendocrine Incidentaloma in a Patient With Sporadic Medullary Thyroid Carcinoma: ...
Next Document:  First Experience DaTSCAN Imaging Using Cadmium-Zinc-Telluride Gamma Camera SPECT.